<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9958">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05686642</url>
  </required_header>
  <id_info>
    <org_study_id>SPH-LT3001-202</org_study_id>
    <nct_id>NCT05686642</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke</brief_title>
  <official_title>A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Efficacy of LT3001 in Subjects With Acute Ischemic Stroke (AIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pharmaceuticals Holding Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pharmaceuticals Holding Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the&#xD;
      treatment of acute ischemic stroke&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2023</start_date>
  <completion_date type="Anticipated">July 12, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Adverse Events</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Adverse event type, incidence, duration, correlation with study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects by mRS（Modified Rankin Scale） score (0 - 2)</measure>
    <time_frame>Day 30 and Day 90 after the first dose</time_frame>
    <description>Proportion of subjects by mRS score (0 - 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an NIHSS（National Institute of Health stroke scale ） score of ≤ 1 point and/or with a decrease of ≥ 4 points from baseline in NIHSS score</measure>
    <time_frame>Day 14 after the first dose</time_frame>
    <description>Proportion of subjects with an NIHSS score of ≤ 1 point and/or with a decrease of ≥ 4 points from baseline in NIHSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in NIHSS score</measure>
    <time_frame>Day 3、Day 7、Day 14 and Day 30 after the first dose</time_frame>
    <description>Absolute change from baseline in NIHSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a BI（Barthel index） score of ≥ 95 points and ≥ 75 points</measure>
    <time_frame>Day 30 and Day 90 after the first dose</time_frame>
    <description>Proportion of subjects with a BI score of ≥ 95 points and ≥ 75 points</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>LT3001 Drug:high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LT3001 Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LT3001 Drug:low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LT3001 Drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LT3001 Drug:high dose</intervention_name>
    <description>Active comparator.Administered by intravenous infusion.</description>
    <arm_group_label>LT3001 Drug:high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator.Administered by intravenous infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LT3001 Drug:low dose</intervention_name>
    <description>Active comparator.Administered by intravenous infusion.</description>
    <arm_group_label>LT3001 Drug:low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged between 18 and 80 years at screening;&#xD;
&#xD;
          2. Clinical diagnosis of acute ischemic stroke that causes evaluable neurological&#xD;
             impairment; 3.4 points ≤ NIHSS score ≤ 25 points at randomization;&#xD;
&#xD;
        4.Subjects who are able to receive the investigational drug within 24 hours after the onset&#xD;
        of stroke; 5.Female subjects of childbearing potential or male subjects whose sexual&#xD;
        partner are women of childbearing potential have no pregnancy plan and voluntarily take&#xD;
        effective contraceptive measures during the study period and for 3 months after the last&#xD;
        dose; 6.All subjects sign the informed consent form by themselves or their guardians after&#xD;
        receiving complete study information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects have received or plan to receive endovascular treatment and/or intravenous&#xD;
             thrombolytic therapy recommended by Chinese Guidelines for Diagnosis and Treatment of&#xD;
             Acute Ischemic Stroke 2018 during this onset period;&#xD;
&#xD;
          2. Presence of disturbances of consciousness at screening and NIHSS 1a ≥ 2 points;&#xD;
&#xD;
          3. Neurological signs have improved rapidly and spontaneously at screening;&#xD;
&#xD;
          4. Subjects who have used or are using protocol-prohibited medications after the onset;&#xD;
&#xD;
          5. Subjects with pre-stroke disability;&#xD;
&#xD;
          6. Subjects with intracranial hemorrhagic diseases, tumor in brain parenchyma,&#xD;
             arteriovenous malformation, aortic arch dissection, other central nervous system&#xD;
             lesions that may increase the risk of hemorrhage, or imaging evidence for arterial&#xD;
             aneurysm requiring treatment;&#xD;
&#xD;
          7. Massive infarction on imaging;&#xD;
&#xD;
          8. Patients who are unable to cooperate due to epileptic seizure at the onset of stroke&#xD;
             or other concomitant mental disorders or are unwilling to cooperate;&#xD;
&#xD;
          9. Systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 100 mmHg after&#xD;
             active antihypertensive therapy;&#xD;
&#xD;
         10. Acute hemorrhage tendency;&#xD;
&#xD;
         11. Blood glucose level &lt; 50 mg/dL or &gt; 400 mg/dL;&#xD;
&#xD;
         12. Active visceral hemorrhage;&#xD;
&#xD;
         13. Lactating or pregnant subjects, or women of childbearing potential with positive&#xD;
             pregnancy test results;&#xD;
&#xD;
         14. International normalized ratio &gt; 1.7 or prothrombin time &gt; 15 s;&#xD;
&#xD;
         15. Subjects with a history of serious hypersensitivity;&#xD;
&#xD;
         16. Subjects who experienced AIS, ICH, acute myocardial infarction or serious head trauma&#xD;
             before screening;&#xD;
&#xD;
         17. Subjects who underwent any major surgery before screening;&#xD;
&#xD;
         18. Subjects with a history of active digestive ulcer before screening;&#xD;
&#xD;
         19. Subjects who experienced hemorrhagic disease before screening;&#xD;
&#xD;
         20. Subjects who underwent arterial puncture at the site not easy for hemostasis by&#xD;
             compression before screening;&#xD;
&#xD;
         21. Serious hepatic impairment or serious renal insufficiency;&#xD;
&#xD;
         22. Subjects who have participated in another investigational study and used&#xD;
             investigational product before screening;&#xD;
&#xD;
         23. Other conditions unsuitable for participation in this study determined by the&#xD;
             Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongjun Wang</last_name>
    <phone>0086-010-59978538</phone>
    <email>Yongjunwang111@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anqing Municipal Hospital</name>
      <address>
        <city>Anqing</city>
        <state>Anhui</state>
        <zip>246000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueying Shi</last_name>
      <phone>0086-0556-5223930</phone>
      <email>aqslyyEC@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of bengbu medical college</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Xie</last_name>
      <phone>0086-0552-3086046</phone>
      <email>byyfyll@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Luhe Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101199</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanling Wang</last_name>
      <phone>0086-010-69543901</phone>
      <email>luhehospital@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>An'ding Xu</last_name>
      <phone>0086-020-38688366</phone>
      <email>2788562962@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harrison International Peace Hospital</name>
      <address>
        <city>Hengshui</city>
        <state>Hebei</state>
        <zip>053099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Wei</last_name>
      <phone>0086-0318-2181234</phone>
      <email>hylq9956@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junyan Liu</last_name>
      <phone>0086-0311-88603000</phone>
      <email>thhmu@cthhmu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daqing Oilfield General Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianghua Liu</last_name>
      <phone>0086-0459-5804127</phone>
      <email>ytzyyrenliziyuan@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luoyang Third People's Hospital</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Sun</last_name>
      <phone>0086-0379-63508088</phone>
      <email>lysyyzxx@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yumin Liu</last_name>
      <phone>0086-027-67812787</phone>
      <email>chenweihua@sphchina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huai'an Second People's Hospital</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <zip>223022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liandong Zhao</last_name>
      <phone>0086-0517-80871603</phone>
      <email>haeyxchk@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deqin Geng</last_name>
      <phone>0086-0516-85802291</phone>
      <email>xyfyec@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pingxiang People's Hospital</name>
      <address>
        <city>Pingxiang</city>
        <state>Jiangxi</state>
        <zip>337000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Yi</last_name>
      <phone>0086-0799-6882099</phone>
      <email>pxsrmyyxxk@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guowen Medical Corporation Jilin Guowen Hospital</name>
      <address>
        <city>Chang chun</city>
        <state>Jilin</state>
        <zip>136199</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinming Ding</last_name>
      <phone>0086-0434-6952614</phone>
      <email>info@hq.gwmc.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Yang</last_name>
      <phone>0086-0431-88782013</phone>
      <email>lunzhijun66@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beipiao Central Hospital</name>
      <address>
        <city>Chaoyang</city>
        <state>Liaoning</state>
        <zip>122199</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yutong Ma</last_name>
      <phone>0086-0421-5080074</phone>
      <email>chenweihua@sphchina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaocheng People's Hospital</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <zip>252004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cunju Guo</last_name>
      <phone>0086-0635-5099120</phone>
      <email>lcsrmyywz@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taian City Central Hospital</name>
      <address>
        <city>Tai'an</city>
        <state>Shandong</state>
        <zip>271099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunlin Liu</last_name>
      <phone>0086-0538-2199516</phone>
      <email>xck8765@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xi'an Gaoxin Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710077</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Jia</last_name>
      <phone>0086-02988332063</phone>
      <email>gxyyec@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yan'an University Xianyang Hospital</name>
      <address>
        <city>Xianyang</city>
        <state>Shanxi</state>
        <zip>716099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Lei</last_name>
      <phone>0086-029-33779387</phone>
      <email>ydxygcp@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaguo Li</last_name>
      <phone>0086-0571-81595231</phone>
      <email>zjyykjkli@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou Municipal Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>318000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Xu</last_name>
      <phone>0086-0576-88805197</phone>
      <email>tzmhgcp@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou First People's Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>318020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhimin Wang</last_name>
      <phone>0086-0576-84016757</phone>
      <email>rsk8787@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjun Wang</last_name>
      <phone>0086-010-59978538</phone>
      <email>Yongjunwang111@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>102218</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Wu</last_name>
      <phone>0086-010-56118567</phone>
      <email>IRB@btch.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pudong Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>201399</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuangxing Hou</last_name>
      <phone>0086-021-68036068</phone>
      <email>pdyyrlb@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 9, 2023</study_first_submitted>
  <study_first_submitted_qc>January 9, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>May 31, 2023</last_update_submitted>
  <last_update_submitted_qc>May 31, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

